Increasing cohort studies have examined the link between mitochondrial DNA copy number (mtDNA-CN) and cardiovascular disease (CVD), with inconsistent findings. We searched PubMed, EMBASE, and Web of Science up to July 11, 2023 and used a random-effects model to calculate summary hazard ratios (HRs) and 95% confidence intervals (CIs). This systematic review and meta-analysis included 8 articles encompassing 29 studies with 646,398 participants. Individuals with the lowest mtDNA-CN had a summary HR of 1.27 (95% CI 1.02-1.59) for CVD, 1.18 (95% CI 0.92-1.50) for coronary heart disease (CHD), 1.10 (95% CI 0.89-1.37) for stroke, and 1.30 (95% CI 1.07-1.56) for heart failure (HF). Decreased mtDNA-CN is linked to an increased risk of CVD and HF but not CHD and stroke. These findings suggest mtDNA-CN from leukocytes may be a potential early biomarker for CVD. However, more prospective studies with long follow-up are needed.
Keyphrases
- mitochondrial dna
- copy number
- cardiovascular disease
- lymph node metastasis
- atrial fibrillation
- heart failure
- genome wide
- acute heart failure
- dna methylation
- type diabetes
- peripheral blood
- case control
- squamous cell carcinoma
- public health
- left ventricular
- cardiovascular risk factors
- coronary artery disease
- metabolic syndrome
- subarachnoid hemorrhage
- cardiac resynchronization therapy